share_log

Allogene Therapeutics To Present Phase 1 Data On ALLO-316 For Advanced CD70 Positive Renal Cell Carcinoma At IKCS And SITC Meetings; FDA Grants RMAT Designation For Potential Single-Infusion AlloCAR T Treatment

Allogene Therapeutics To Present Phase 1 Data On ALLO-316 For Advanced CD70 Positive Renal Cell Carcinoma At IKCS And SITC Meetings; FDA Grants RMAT Designation For Potential Single-Infusion AlloCAR T Treatment

allogene therapeutics将在IKCS和海丰国际会议上发布ALLO-316用于爱文思控股CD70阳性肾细胞癌的1期数据;FDA授予RMAt标志潜在单次注射AlloCAR t治疗
Benzinga ·  11/05 22:11

Allogene Therapeutics To Present Phase 1 Data On ALLO-316 For Advanced CD70 Positive Renal Cell Carcinoma At IKCS And SITC Meetings; FDA Grants RMAT Designation For Potential Single-Infusion AlloCAR T Treatment

allogene therapeutics将在IKCS和海丰国际会议上发布ALLO-316用于爱文思控股CD70阳性肾细胞癌的1期数据;FDA授予RMAt标志潜在单次注射AlloCAR t治疗

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发